Literature DB >> 23079588

Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions.

Isabelle Soerjomataram1, Joannie Lortet-Tieulent, D Maxwell Parkin, Jacques Ferlay, Colin Mathers, David Forman, Freddie Bray.   

Abstract

BACKGROUND: Country comparisons that consider the effect of fatal and non-fatal disease outcomes are needed for health-care planning. We calculated disability-adjusted life-years (DALYs) to estimate the global burden of cancer in 2008.
METHODS: We used population-based data, mostly from cancer registries, for incidence, mortality, life expectancy, disease duration, and age at onset and death, alongside proportions of patients who were treated and living with sequelae or regarded as cured, to calculate years of life lost (YLLs) and years lived with disability (YLDs). We used YLLs and YLDs to derive DALYs for 27 sites of cancers in 184 countries in 12 world regions. Estimates were grouped into four categories based on a country's human development index (HDI). We applied zero discounting and uniform age weighting, and age-standardised rates to enable cross-country and regional comparisons.
FINDINGS: Worldwide, an estimated 169·3 million years of healthy life were lost because of cancer in 2008. Colorectal, lung, breast, and prostate cancers were the main contributors to total DALYs in most world regions and caused 18-50% of the total cancer burden. We estimated an additional burden of 25% from infection-related cancers (liver, stomach, and cervical) in sub-Saharan Africa, and 27% in eastern Asia. We noted substantial global differences in the cancer profile of DALYs by country and region; however, YLLs were the most important component of DALYs in all countries and for all cancers, and contributed to more than 90% of the total burden. Nonetheless, low-resource settings had consistently higher YLLs (as a proportion of total DALYs) than did high-resource settings.
INTERPRETATION: Age-adjusted DALYs lost from cancer are substantial, irrespective of world region. The consistently larger proportions of YLLs in low HDI than in high HDI countries indicate substantial inequalities in prognosis after diagnosis, related to degree of human development. Therefore, radical improvement in cancer care is needed in low-resource countries. FUNDING: Dutch Scientific Society, Erasmus University Rotterdam, and International Agency for research on Cancer.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23079588     DOI: 10.1016/S0140-6736(12)60919-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  223 in total

1.  Association between the FTOrs8050136 polymorphism and cancer risk: a meta-analysis.

Authors:  Jian Zhao; Xiaoyi Huang; Mingyuan Yang; Ming Li; Jianming Zheng
Journal:  Fam Cancer       Date:  2016-01       Impact factor: 2.375

2.  [Economic importance of postoperative urinary incontinence].

Authors:  V Lent; M Schultheis
Journal:  Urologe A       Date:  2015-11       Impact factor: 0.639

3.  Supporting respiratory function in the immunocompromised critically ill patient: new perspectives for an old paradigm.

Authors:  Lorenzo Ball; Paolo Pelosi
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

Review 4.  Cholecystectomy and the risk of alimentary tract cancers: a systematic review.

Authors:  Maria Coats; Sami M Shimi
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

5.  Wilms tumor survival in Kenya.

Authors:  Jason Axt; Fatmah Abdallah; Meridith Axt; Jessie Githanga; Erik Hansen; Joel Lessan; Ming Li; Joyce Musimbi; Michael Mwachiro; Mark Newton; James Ndung'u; Festis Njuguna; Ancent Nzioka; Oliver Oruko; Kirtika Patel; Robert Tenge; Flora Ukoli; Russel White; James A O'Neill; Harold N Lovvorn
Journal:  J Pediatr Surg       Date:  2013-06       Impact factor: 2.545

6.  Comparing 3 values clarification methods for colorectal cancer screening decision-making: a randomized trial in the US and Australia.

Authors:  Alison Brenner; Kirsten Howard; Carmen Lewis; Stacey Sheridan; Trisha Crutchfield; Sarah Hawley; Dan Reuland; Christine Kistler; Michael Pignone
Journal:  J Gen Intern Med       Date:  2013-11-23       Impact factor: 5.128

7.  Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.

Authors:  Claudia Allemani; Tomohiro Matsuda; Veronica Di Carlo; Rhea Harewood; Melissa Matz; Maja Nikšić; Audrey Bonaventure; Mikhail Valkov; Christopher J Johnson; Jacques Estève; Olufemi J Ogunbiyi; Gulnar Azevedo E Silva; Wan-Qing Chen; Sultan Eser; Gerda Engholm; Charles A Stiller; Alain Monnereau; Ryan R Woods; Otto Visser; Gek Hsiang Lim; Joanne Aitken; Hannah K Weir; Michel P Coleman
Journal:  Lancet       Date:  2018-01-31       Impact factor: 79.321

8.  Rapamycin enhances cetuximab cytotoxicity by inhibiting mTOR-mediated drug resistance in mesenchymal hepatoma cells.

Authors:  Wei Chen; Qi-Da Hu; Xue-Feng Xia; Chao Liang; Hao Liu; Qi Zhang; Tao Ma; Feng Liang; Ting-Bo Liang
Journal:  Cancer Biol Ther       Date:  2014-05-06       Impact factor: 4.742

9.  An Investigation into the Recent Increase in Gastric Cancer in the USA.

Authors:  Maya Balakrishnan; Rollin George; Ashish Sharma; David Y Graham; Hoda M Malaty
Journal:  Dig Dis Sci       Date:  2018-03-15       Impact factor: 3.199

10.  The polymorphism rs975484 in the protein arginine methyltransferase 1 gene modulates expression of immune checkpoint genes in hepatocellular carcinoma.

Authors:  Michael Schonfeld; Jie Zhao; Amberly Komatz; Steven A Weinman; Irina Tikhanovich
Journal:  J Biol Chem       Date:  2020-04-03       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.